Q2 & H1 FY22 RESULT HIGHLIGHTS: Net Revenue at Rs 4,589.0 mn in Q2 FY22 up by 4.4% YoY CRAMS revenue remained flat increasing by 0.3% YoY primarily due to: CRAMS India revenue increased by 560.7% due to resumption of servicing of CRAMS orders after clearances received from customers CRAMS - Switzerland, France & China revenue decreased by 11.8% due to deferment of supply of certain commercial products already produced to the next quarter according to the customer requirements. Marketable Molecules revenue increased 19.9% YoY primarily due to Carbogen Amcis BV revenue increased by 36.3% due to increase in demand for cholesterol and Vitamin D analogues globally. EBITDA Margin increased to 21.6% in Q2 FY22 due to: CRAMS India registering significant growth in the high margin CRAMS business. Carbogen Amcis AG maintaining healthy margins at 20% Carbogen Amcis UK margins increased due to supply of higher value intermediates and starting materials. Net Debt excluding lease liabilities was USD 101 mn as on September 30, 2021 (USD 101 mn as on June 30, 2021). Capital expenditure for H1 FY22 was approximately USD 31.85 mn, which majorly includes capex at Swiss and French sites. Result PDF